The Oystar Group has bundled its U.S. business under a single corporate umbrella. With immediate effect, the previous U.S. subsidiaries Oystar Jones (Covington, KY), Oystar USA (Edison, NJ) and Oystar Packaging Technologies (Davenport, IA) will now have a uniform corporate appearance as “Oystar North America.”
Pharmaworks, Inc. (Odessa, FL) has announced the release of the TF1e blister packaging machine. Built on the success of the TF1 blister machine, the TF1e has an increased format range (170 mm x 90 mm vs. 130 mm x 80 mm). The company is positioning the TF1e as an affordable, small footprint machine, well suited for today’s quick changeover demands.
With finances back on a solid footing, the company plans investment in its pharma and medical device businesses.
Tekni-Plex, Inc. (King of Prussia, PA) is focused on growing its pharmaceutical packaging and medical device business segments, after implementing broad reforms to restore corporate profitability.
Since a financial restructuring two years ago, the global manufacturer of packaging and tubing products has maintained investment in its core businesses, and is planning for continued growth, says Paul Young, CEO, Tekni-Plex.
In blister materials, pharmaceutical companies' first priority is protecting the product, and at the lowest possible cost. Material performance on the packaging line is another issue to be considered, with pharma firms focused on improving line uptimes and speed.
Catalent Pharma Solutions (Somerset, NJ) has installed and qualified a ZED in-line blister card sealer at its Clinical Supply Services facility in Philadelphia that provides flexibility for both small and high-volume clinical trial packaging. The sealer automatically places blister cards and strips, deploying dual sealing stations that assist in cutting blister sealing time in half and speeding production.
Victory Pharma (San Diego) has launched the Naprelan Dose Card, an extension of its Naprelan franchise. The Dose Card provides a ten-day tapered dose regimen in a single blister pack. Three days of Naprelan therapy at the maximum daily dose of 1,500 mg (two 750 mg tablets) are followed by a taper to 1,000 mg per day (two 500 mg tabs) for an additional seven days of therapy.
McKesson has launched the PROmanager-Rx system for hospital pharmacy dispensing of product pre-packaged by manufacturers in unit-dose bar-coded format.